| Authors: |
Topp MS; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany., Matasar M; Division of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ., Allan JN; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY., Ansell SM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN., Barnes JA; Department of Medicine, Hematology and Oncology Division, Massachusetts General Hospital Cancer Center, Boston, MA., Arnason JE; Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA., Michot JM; Departement D'Innovation Therapeutique et D'Essais Precoces, Gustave Roussy Cancer Campus, Villejuif, France., Goldschmidt N; Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel., O'Brien SM; Division of Hematology/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA., Abadi U; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Hematology, Meir Medical Center, Kfar Saba, Israel., Avivi I; Department of Hematology, Ichilov University Hospital, Tel Aviv, Israel., Cheng Y; Regeneron Pharmaceuticals, Inc., Tarrytown, NY., Flink DM; Regeneron Pharmaceuticals, Inc., Tarrytown, NY., Zhu M; Regeneron Pharmaceuticals, Inc., Tarrytown, NY., Brouwer-Visser J; Regeneron Pharmaceuticals, Inc., Tarrytown, NY., Chaudhry A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY., Mohamed H; Regeneron Pharmaceuticals, Inc., Tarrytown, NY., Ambati S; Regeneron Pharmaceuticals, Inc., Tarrytown, NY., Crombie JL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. |
